Department of Surgery, University of Alberta, Edmonton, AB, Canada.
St. George's University, University Centre, Grenada, West Indies.
Eur J Surg Oncol. 2015 Jan;41(1):120-7. doi: 10.1016/j.ejso.2014.09.007. Epub 2014 Oct 7.
Radioembolization with yttrium-90 microspheres offers an alternative treatment option for patients with unresectable intrahepatic cholangiocarcinoma (ICC). However, the rarity and heterogeneity of ICC makes it difficult to draw firm conclusions about treatment efficacy. Therefore, the goal of the current study is to systematically review the existing literature surrounding treatment of unresectable ICCs with yttrium-90 microspheres and provide a comprehensive review of the current experience and clinical outcome of this treatment modality. We performed a comprehensive search of electronic databases for ICC treatment and identified 12 studies with relevant data regarding radioembolization therapy with yttrium-90 microspheres. Based on pooled analysis, the overall weighted median survival was 15.5 months. Tumour response based on radiological studies demonstrated a partial response in 28% and stable disease in 54% of patients at three months. Seven patients were able to be downstaged to surgical resection. The complication profile of radioembolization is similar to that of other intra-arterial treatment modalities. Overall survival of patients with ICC after treatment with yttrium-90 microspheres is higher than historical survival rates and shows similar survival to those patients treated with systemic chemotherapy and/or trans-arterial chemoembolization therapy. Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC. However, future randomized trials comparing systemic chemotherapy, TACE and local radiation will be required to identify the optimal treatment modality for unresectable ICC.
钇 90 微球放射性栓塞为不可切除的肝内胆管细胞癌 (ICC) 患者提供了一种替代治疗选择。然而,ICC 的罕见性和异质性使得很难对治疗效果得出确凿的结论。因此,目前的研究目标是系统地回顾围绕钇 90 微球治疗不可切除的 ICC 的现有文献,并全面回顾这种治疗方式的现有经验和临床结果。我们对 ICC 治疗的电子数据库进行了全面搜索,并确定了 12 项具有关于钇 90 微球放射性栓塞治疗相关数据的研究。基于汇总分析,总体加权中位数生存为 15.5 个月。根据影像学研究,三个月时肿瘤反应显示部分缓解率为 28%,稳定疾病率为 54%。7 名患者能够降期进行手术切除。放射性栓塞的并发症谱与其他动脉内治疗方式相似。接受钇 90 微球治疗后 ICC 患者的总生存率高于历史生存率,与接受系统化疗和/或经动脉化疗栓塞治疗的患者的生存率相似。因此,在 ICC 的可用治疗方案列表中应考虑使用钇 90 微球。然而,未来需要进行比较系统化疗、TACE 和局部放疗的随机试验,以确定不可切除的 ICC 的最佳治疗方式。